What is the half-life of apixaban?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 26, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Apixaban Half-Life

Apixaban has an apparent half-life of approximately 12 hours following oral administration in patients with normal renal function. 1, 2

Standard Half-Life Parameters

  • The terminal plasma half-life ranges from 8-14 hours in healthy subjects, with the most commonly cited value being 12 hours 1
  • Maximum plasma concentrations occur 3-4 hours after oral administration 2, 3
  • Steady-state anticoagulant effects are achieved within 3 days of twice-daily dosing 1
  • Total clearance is approximately 3.3 L/hour 2

Impact of Renal Function on Half-Life

Renal impairment significantly prolongs apixaban's half-life, which is clinically critical since approximately 27% of total drug clearance occurs via renal excretion 1, 2:

  • Normal renal function (CrCl ≥80 mL/min): ~12 hours 1
  • Mild impairment (CrCl 50-79 mL/min): ~15 hours 1
  • Moderate impairment (CrCl 30-49 mL/min): ~18 hours 1
  • Severe impairment (CrCl 15-29 mL/min): ~27 hours 1
  • End-stage renal disease (CrCl <15 mL/min): ~30 hours off dialysis 1

Clinical Pitfall: Genetic Polymorphisms

  • Concurrent genetic polymorphisms affecting multiple elimination pathways can dramatically prolong the half-life, as demonstrated in a case report where a patient with CYP3A5*3/*3, ABCG2 c.421C/A, and homozygous ABCB1 polymorphisms exhibited a half-life of approximately 31 hours despite only moderate renal impairment 4
  • This resulted in apixaban concentrations 20-fold higher than expected 4

Procedural Planning Based on Half-Life

For high-risk procedures, discontinuation timing should be adjusted based on renal function 1:

  • CrCl >80 mL/min: Discontinue 2 days before procedure 1
  • CrCl 50-80 mL/min: Discontinue 2 days before procedure 1
  • CrCl 30-50 mL/min: Discontinue 2 days before procedure 1

Important Caveat for Bleeding Management

  • For non-life-threatening bleeding, temporary cessation may be sufficient due to the relatively short 12-hour half-life 1
  • Activated charcoal is most effective within 3 hours of the last dose, coinciding with peak plasma concentration at 3-4 hours 1
  • In documented overdose cases, even with massive ingestions, the elimination half-life remained approximately 14 hours with first-order kinetics in the presence of impaired renal function 5

Related Questions

What is the half-life of apixaban (Eliquis)?
What is the half-life of apixaban?
What is the half-life of Eliquis (apixaban)?
What is the half-life of Eliquis (apixaban)?
What is the best approach for anticoagulation in a patient with cardiogenic shock, impaired renal function on continuous venovenous hemodialysis (CVVHD) and ultrafiltration, who has been on apixaban (eliquis) with a current anti-Xa level of 1.2, and is experiencing thrombocytopenia while on continuous renal replacement therapy (CRRT)?
What is the recommended dose of Bromfed DM (Brompheniramine, Dextromethorphan, and Guaifenesin) for a 63-pound pediatric patient?
What are the potential risks and management strategies for a patient taking multiple medications, including those that may prolong the QT interval, and how should their medication regimen be monitored and adjusted to minimize interactions and side effects?
What is a suitable alternative to metaxalone for an adult patient with severe muscle spasms and potential liver or kidney disease?
What is the best course of treatment for an 11-month-old infant with recurrent bilateral Acute Otitis Media (AOM), who has had 3 ear infections in the last 2 months and was previously treated with amoxicillin, azithromycin, and cefprozil?
What could be the cause of a rapidly growing lump on the back of a patient with a family history of melanoma, but with normal overlying skin?
For a patient with a long-standing hepatitis B (HBV) carrier state and a negative hepatitis D (HDV) antibody test, do I still need to screen for HDV RNA?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.